← All Signals

🏥 FDA: Amerisource Health Services LLC — Class II

healthcareneutralSource: FDA
75%Confidence
0Views
FDASource
2026-04-09Date

Summary

Amerisource Health Services recalls Meclizine tablets due to failed specifications, indicating quality control lapses in a common anti-nausea medication distributed by American Health Packaging. This may affect the distributor's reliability and prompt customers to seek alternative suppliers for over-the-counter and prescription nausea treatments.

Actionable: Watch for competitor gains in the anti-nausea market as Amerisource addresses this recall.

AI Confidence: 75%

Data Points

firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionU.S. Nationwide
productMeclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Dis

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now